ERBB3 and melanoma: Studies have shown that SOX10 contributes to melanoma’s adaptive resistance to RAF inhibitors via the ERK1/2/SOX10/FOXD3/ERBB3 signaling pathway (28).The imperative for developing a prognostic model based on SOX10 is to enhance melanoma patients’ survival rates and refine treatment strategies.